Universal Blood Test Detects and Tracks Sarcoma Across All Subtypes

Sarcomas — cancers of bone and soft tissue — are among the hardest malignancies to monitor. Unlike common cancers such as breast or colon, sarcomas lack a reliable circulating biomarker, making it difficult to assess treatment response or detect early relapse through blood tests alone. This study addresses that gap with a potentially transformative tool.

Researchers from Paris used computational analysis of over 8,300 tumor samples to identify DNA methylation patterns unique to sarcoma cells — present in tumor tissue but absent in healthy blood cells and surrounding tissues. They then engineered a droplet digital PCR assay targeting seven of these hypermethylated genomic sites, capable of detecting as little as 0.06% methylated allele frequency in circulating cell-free DNA.

The assay was validated in two patient cohorts: 49 patients with metastatic soft-tissue sarcoma and 42 patients receiving neoadjuvant (pre-surgical) chemotherapy. ctDNA was detected in 45% of metastatic patients and 74% of neoadjuvant patients across a combined 23 histological subtypes. In metastatic patients, ctDNA positivity was significantly associated with worse overall survival. In the neoadjuvant group, rising ctDNA during chemotherapy strongly predicted poor histologic response, radiological progression, or relapse within six months.

These results suggest the assay could serve as a real-time tumor burden monitor — helping oncologists gauge whether chemotherapy is working before imaging changes become apparent. For surgical planning, early ctDNA dynamics may help identify patients unlikely to benefit from their current regimen.

Caveats include the moderate detection rate in metastatic patients (45%), which may limit utility in lower-burden disease. The study is relatively small, and the assay has not yet been validated in prospective trials. Summary is based on the abstract only.